Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00007969 · ClinicalTrials.gov registry record · Phase 1

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

A Phase 1 study, sponsored by QLT.

Completed
Registry status
Phase 1
Development phase

NCT00007969 is a Phase 1 study that has completed, run by QLT.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00007969, a Phase 1 study, has completed, sponsored by QLT.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy may be effective in treating melanoma. PURPOSE: Phase I/II trial to study the effectiveness of photodynamic therapy in treating patients who have stage III or stage IV melanoma.

Interventions

  • DRUG verteporfin
  • BIOLOGICAL Detox-B adjuvant

Trial Details

FieldValue
Start Date 2000-10
Phase Phase 1

Sponsor

QLT

10 total trials

What the Registry Record Tells You About NCT00007969

The ClinicalTrials.gov registry entry for NCT00007969 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is QLT, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which verteporfin is the first listed.

NCT00007969 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00007969 about?

NCT00007969 is a clinical study titled "Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy may be effective in treating melanoma. PURPOSE: Phase I/II trial to study the effectiveness of photodynamic therapy in treating patients who have stage III o...

What is the current status of trial NCT00007969?

This trial is currently completed. It is a Phase 1 study. The study started on 2000-10.

What interventions are being tested in trial NCT00007969?

The interventions under investigation include: verteporfin (DRUG), Detox-B adjuvant (BIOLOGICAL).

Who is sponsoring clinical trial NCT00007969?

This trial is sponsored by QLT, which has 10 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.